Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
默沙東與翰森製藥簽署獨家全球許可協議,針對研究性口服GLP-1受體激動劑。
Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
默沙東與翰森製藥簽署獨家全球許可協議,針對研究性口服GLP-1受體激動劑。
使用瀏覽器的分享功能,分享給你的好友吧